CTLA4 and melanoma: A phase III study, the CheckMate-067 trial, investigated the efficacy of the PD-1 inhibitor nivolumab with the CTLA-4 inhibitor ipilimumab compared to monotherapies in patients with advanced melanoma who had not received treatment.